Entinostat

What is Entinostat?

Entinostat is an investigational drug classified as a histone deacetylase (HDAC) inhibitor. It represents a class of compounds known as epigenetic therapy agents, which work by targeting processes that control gene expression without altering the underlying DNA sequence. Specifically, Entinostat has been extensively studied for its potential in cancer treatment, particularly in various solid tumors. While not universally approved for all indications, its unique mechanism of action has positioned it as a significant focus in oncology research, aiming to provide new therapeutic avenues for patients with difficult-to-treat cancers.

How Does it Work?

The primary mechanism of action for Entinostat involves the selective inhibition of certain histone deacetylase enzymes. HDACs are proteins that play a crucial role in gene regulation by removing acetyl groups from histones, which are proteins that package DNA. When histones are deacetylated, the DNA becomes more tightly wound, making it inaccessible for transcription and thus silencing gene expression. By inhibiting these enzymes, Entinostat leads to an increase in histone acetylation, a process known as hyperacetylation.

This hyperacetylation causes the DNA to become unwound and more accessible, leading to altered gene expression. In cancer cells, this can reactivate tumor suppressor genes, inhibit cell proliferation, induce differentiation, and promote programmed cell death (apoptosis). Entinostat primarily inhibits Class I HDACs (HDAC1, HDAC3, HDAC8) and to a lesser extent, Class IIb HDAC6. Beyond its direct effects on tumor cells, Entinostat also exhibits immunomodulatory properties, potentially enhancing the effectiveness of other anti-cancer therapies by influencing the tumor microenvironment and immune response.

Medical Uses

Entinostat has been primarily investigated in clinical trials for a range of advanced cancers. Its most prominent research focus has been in advanced hormone receptor-positive, HER2-negative breast cancer. In this setting, it was studied in combination with exemestane, an aromatase inhibitor, and received Breakthrough Therapy Designation from the FDA, though the subsequent clinical trial results did not meet the primary endpoint for overall survival, leading to the withdrawal of the application. Despite this, Entinostat continues to be explored for its potential in other malignancies.

• Breast Cancer: Especially in advanced hormone receptor-positive, HER2-negative subtypes.
• Non-Small Cell Lung Cancer (NSCLC): Investigated in combination with immunotherapy or chemotherapy.
• Melanoma: Explored for its potential to enhance responses to immunotherapy.
• Colorectal Cancer: Clinical trials have evaluated its efficacy in specific patient populations.
• Other Solid Tumors: Ongoing research continues to assess its utility in various other cancer types, often in combination with existing standard treatments or novel agents.

It is important to note that the use of Entinostat is largely confined to clinical trial settings or specific compassionate use programs, as it does not hold broad regulatory approval for general clinical use at this time.

Dosage

As an investigational drug, the precise dosage of Entinostat is typically determined within the context of clinical trials and tailored to specific study protocols. However, it is generally administered orally. Common dosing regimens in trials have involved intermittent schedules, such as once weekly, to manage potential side effects and optimize therapeutic efficacy. The dosage can vary significantly based on the type of cancer being treated, whether it's used as a monotherapy or in combination with other drugs, and the patient's individual response and tolerability.

Patients participating in clinical trials will receive specific instructions from their healthcare providers regarding the exact dosage, frequency, and duration of treatment. It is crucial for patients to adhere strictly to these instructions and to report any adverse reactions or concerns to their medical team promptly. Self-medication or altering the prescribed dosage without medical guidance is strongly discouraged.

Side Effects

Like all potent therapeutic agents, Entinostat can cause a range of side effects, which vary in severity among individuals. The most commonly reported adverse events during clinical trials include:

• Fatigue: A frequent complaint, often mild to moderate.
• Gastrointestinal Issues: Nausea, vomiting, diarrhea, and decreased appetite.
• Hematologic Abnormalities: These can include thrombocytopenia (low platelet count), neutropenia (low white blood cell count), and anemia (low red blood cell count). Regular blood monitoring is often required.
• Elevated Liver Enzymes: Increases in liver function tests, such as ALT and AST, which typically resolve upon dose adjustment or discontinuation.
• Other Side Effects: Less common but reported effects include dysgeusia (taste disturbance), weight loss, and peripheral edema.

Patients receiving Entinostat should be closely monitored by their healthcare team for these and other potential side effects. Prompt reporting of any new or worsening symptoms is essential for appropriate management and dose adjustments.

Drug Interactions

Entinostat is metabolized primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system. This means it has the potential for significant drug interactions with other medications that either inhibit or induce CYP3A4 activity. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can increase Entinostat plasma concentrations, potentially leading to increased toxicity. Conversely, strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John's Wort) can decrease Entinostat concentrations, potentially reducing its efficacy.

Additionally, caution is advised when Entinostat is used concurrently with drugs known to prolong the QT interval, as Entinostat itself has shown some potential for QT prolongation in preclinical studies. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to allow for proper assessment of potential drug interactions and necessary dose adjustments or alternative treatments. Regular monitoring for adverse events and drug levels may be required when co-administering with interacting substances.

FAQ

Q: Is Entinostat approved for all types of cancer?

A: No, Entinostat is currently an investigational drug. Its use is primarily within clinical trials for specific types of advanced cancers, such as certain breast cancer subtypes, non-small cell lung cancer, and melanoma. It does not have broad regulatory approval for general clinical use.

Q: How is Entinostat administered?

A: Entinostat is typically administered orally, often on an intermittent schedule, such as once weekly, as determined by clinical trial protocols.

Q: What is an HDAC inhibitor?

A: An HDAC inhibitor is a type of drug that blocks the activity of histone deacetylase enzymes. These enzymes play a role in gene regulation, and by inhibiting them, HDAC inhibitors can alter gene expression in cancer cells, potentially leading to cell cycle arrest and cell death.

Q: Can Entinostat be used as a standalone treatment?

A: While it has been studied as a monotherapy, Entinostat is often investigated in combination with other anti-cancer agents, such as chemotherapy, endocrine therapy, or immunotherapy, to enhance overall treatment efficacy.

Q: What are the most common side effects of Entinostat?

A: Common side effects include fatigue, gastrointestinal issues (nausea, vomiting, diarrhea), and blood count abnormalities like thrombocytopenia, neutropenia, and anemia.

Products containing Entinostat are available through trusted online pharmacies. You can browse Entinostat-based medications at ShipperVIP or Medicenter.

Summary

Entinostat is an investigational HDAC inhibitor that holds promise as an epigenetic therapy in the field of cancer treatment. Its mechanism of action involves altering gene expression in cancer cells by inhibiting specific histone deacetylase enzymes, leading to effects such as cell cycle arrest and apoptosis. While not yet broadly approved, Entinostat has been extensively evaluated in clinical trials for various advanced malignancies, including breast cancer, NSCLC, and melanoma, often in combination with other therapies. Patients considering or receiving Entinostat should be aware of its potential side effects, which include fatigue, gastrointestinal issues, and hematologic abnormalities, and its drug interaction profile, particularly with CYP3A4 modulators. Ongoing research continues to explore its full therapeutic potential and optimize its role in the evolving landscape of oncology.